Endocrine Properties and Clinical Application of Danazol (Q39793331)

14 September 2017

1 reference

title

Endocrine Properties and Clinical Application of Danazol (English)

1 reference

https://api.crossref.org/works/10.1016/S0015-0282(16)43869-0

11 April 2023

author name string

W. P. Dmowski

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A374128

11 April 2023

language of work or name

English

0 references

publication date

1 March 1979

1 reference

full work available at URL

14 September 2017

https://api.elsevier.com/content/article/PII:S0015028216438690?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0015-0282(16)43869-0

https://api.elsevier.com/content/article/PII:S0015028216438690?httpAccept=text/plain

11 April 2023

1 reference

https://api.crossref.org/works/10.1016/S0015-0282(16)43869-0

11 April 2023

published in

Fertility and Sterility

1 reference

14 September 2017

volume

31

1 reference

14 September 2017

issue

3

1 reference

14 September 2017

page(s)

237-251

1 reference

STEROIDAL HETEROCYCLES. VII. ANDROSTANO(2,3-D)ISOXAZOLES AND RELATED COMPOUNDS

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2943869-0

7 January 2021

Danazol—a Synthetic Steroid Derivative with Interesting Physiologic Properties

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2943869-0

7 January 2021

A competitive radioligand assay for danazol (17α-pregn-4-en-20-yno[2,3-d]isoxazol-17-ol) using pregnant guinea pig plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2943869-0

7 January 2021

A radioimmunoassay for danazol (17alpha-pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol)

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2943869-0

7 January 2021

Isolation, synthesis, and biological activity of five metabolites of danazol

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2943869-0

7 January 2021

Pituitary Gonadotropin Inhibitory Activity of Danazol

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2943869-0

7 January 2021

Effects of castration of immature rats on serum FSH and LH, and of various steroid treatments after castration

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2943869-0

7 January 2021

Danazol effects on gonadotropin basal levels and pituitary responsiveness to LH-RH in immature male rats

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2943869-0

7 January 2021

Effects of danazol on gonadotropin secretion after ovariectomy in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2943869-0

7 January 2021

Clinical Studies with an Antigonadotropin-Danazol

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2943869-0

7 January 2021

Adrenal Function During Chronic Danazol Administration

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2943869-0

7 January 2021

Treatment of endometriosis with Danazol

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2943869-0

7 January 2021

Antigonadotropin (danazol) in the treatment of endometriosis. Evaluation of posttreatment fertility and three-year follow-up data

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2943869-0

7 January 2021

Danazol: An Antigonadotrophic Agent in the Treatment of Recurrent Pelvic and Intestinal Endometriosis

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2943869-0

7 January 2021

Danazol: An antigonadotropic agent in the treatment of pelvic endometriosis

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2943869-0

7 January 2021

The use of an impeded androgen--danazol--in the management of benign breast disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2943869-0

7 January 2021

Oral contraceptive activity of danazol in the rhesus monkey

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2943869-0

7 January 2021

Pituitary and testicular function studies. I. Experience with a new gonadal inhibitor, 17-alpha-pregn-4-en-20-yno-(2,3-d)isoxazol-17-ol (Danazol).

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2943869-0

7 January 2021

Changes in sperm morphology in normal men treated with danazol and testosterone

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2943869-0

7 January 2021

Investigation of Danazol as a contraceptive agent

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2943869-0

7 January 2021

Intermittent therapy with danazol in hereditary angioedema

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2943869-0

7 January 2021

Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2943869-0

7 January 2021

Danazol plasma concentration in man

9

1 reference

https://api.crossref.org/works/10.1016/S0015-0282(16)43869-0

Pituitary Gonadotropin Responsiveness with Danazol

11 April 2023

16

1 reference

https://api.crossref.org/works/10.1016/S0015-0282(16)43869-0

Contraceptive properties of Danazol

11 April 2023

19

1 reference

https://api.crossref.org/works/10.1016/S0015-0282(16)43869-0

Endocrine effects of danazol in menstruating women

11 April 2023

20

1 reference

https://api.crossref.org/works/10.1016/S0015-0282(16)43869-0

Hormonal changes associated with Danazol therapy

11 April 2023

21

1 reference

https://api.crossref.org/works/10.1016/S0015-0282(16)43869-0

The effects of danazol on gonadotropins and steroid blood levels in normal and anovulatory women

11 April 2023

22

1 reference

https://api.crossref.org/works/10.1016/S0015-0282(16)43869-0

Danazol in the treatment of hereditary angio-neurotic oedema

11 April 2023

25

1 reference

https://api.crossref.org/works/10.1016/S0015-0282(16)43869-0

Danazol treatment and follow-up of patients with endometriosis

11 April 2023

29

1 reference

https://api.crossref.org/works/10.1016/S0015-0282(16)43869-0

The use of danazol in the management of endometriosis

11 April 2023

33

1 reference

https://api.crossref.org/works/10.1016/S0015-0282(16)43869-0

Preliminary observations on the use of danazol in endometriosis compared to oestrogen/progestogen combination therapy

11 April 2023

35

1 reference

https://api.crossref.org/works/10.1016/S0015-0282(16)43869-0

Dosage aspects of danazol therapy in endometriosis

11 April 2023

37

1 reference

https://api.crossref.org/works/10.1016/S0015-0282(16)43869-0

Danazol in the treatment of benign breast disease

11 April 2023

39

1 reference

https://api.crossref.org/works/10.1016/S0015-0282(16)43869-0

The effect of danazol in sexual precocity

11 April 2023

45

1 reference

https://api.crossref.org/works/10.1016/S0015-0282(16)43869-0

Fertility in the Rhesus Monkey Following Long-Term Inhibition of Ovarian Function with Danazol

11 April 2023

47

1 reference

https://api.crossref.org/works/10.1016/S0015-0282(16)43869-0

Influence of Danazol (100 mg) on conception and contraception

11 April 2023

53

1 reference

https://api.crossref.org/works/10.1016/S0015-0282(16)43869-0

11 April 2023

Identifiers

0 references

1 reference